Revolution Medicines, Inc. is 2.3x more valuable than EXELIXIS, INC. by market capitalization ($30.74 B vs $13.22 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | EXEL | RVMD |
|---|---|---|
| Market cap | $13.22 B | $30.74 B |
| US-listed rank | #789 | #453 |
| Revenue (latest FY) | $2.32B | $0.00 |
| Net income (latest FY) | $782.60M | -$1.13B |
| Net margin | 33.7% | - |
| P/E (trailing FY) | 16.9 | - |
| SEC filings | 2,488 | 782 |
Revolution Medicines, Inc. is 2.3x more valuable than EXELIXIS, INC. by market capitalization ($30.74 B vs $13.22 B).
In their latest fiscal years, EXELIXIS, INC. reported $2.32B in revenue while Revolution Medicines, Inc. reported $0.00.
Full pages: EXELIXIS, INC. and Revolution Medicines, Inc., or browse the full rankings.